Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to gram-positive cocci

Infectious Diseases in Clinical Practice

Volumn 17, Issue 1, 2009, Pages 17-21

  Hermsen, Elizabeth D ^a,b,c   Shull, Sara S ^a   Mitropoulos, Isaac F ^a   Puumala, Susan E ^d   Rupp, Mark E ^c  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Dick Holland Regenerative Medicine Program   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; DAPTOMYCIN; LINEZOLID; OXACILLIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC ASPECT; ENDOCARDITIS; FEMALE; GRAM POSITIVE COCCI; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OSTEOMYELITIS; SKIN INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 68049098205     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e318184d74e     Document Type: Article

References (19)

1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394-e434.
2. Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am. 2005;19:765-786.
3. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
4. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
5. Falagas ME, Giannopoulou KP, Ntziora F, et al. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents. 2007;30(3):202-209.
6. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant gram-positive bone and joint infections. Curr Med Res Opin. 2005;21:1923-1926.
7. Juthani-Mehta M. Successful therapy of methicillin resistant Staphylococcus aureus (MRSA) vertebral osteomyelitis (VOM) with daptomycin. October 9-12, 2003. San Diego, CA.
8. Aneziokoro CO, Cannon JP, Pachucki CT, et al. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother. 2005;17:643-650.
9. Falagas ME, Siempos II, Papagelopoulos PJ, et al. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents. 2007;29:233-239.
10. Harwood PJ, Giannoudis PV. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin Drug Saf. 2004;3:405-414.
11. Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32:8-14.
12. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273-280.
13. Munoz P, Rodriguez-Creixems M, Moreno M, et al. Linezolid therapy for infective endocarditis. Clin Microbiol Infect. 2007;13:211-215.
14. Wareham DW, Abbas H, Karcher AM, et al. Treatment of prosthetic valve infective endocarditis due to multi-resistant gram-positive bacteria with linezolid. J Infect. 2006;52:300-304.
15. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-2152.
16. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin. 2006;22:2337-2343.
17. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006;26:347-352.
18. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
19. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260-2266.